Retinal pigment epithelium (RPE) dysfunction and loss are a hallmark of non-neovascular age-related macular degeneration (NNAMD). Without the RPE, a majority of overlying photoreceptors ultimately degenerate, leading to severe, progressive vision loss. Clinical and histological studies suggest that RPE replacement strategies may delay disease progression or restore vision.
Regenerative Patch Technologies has developed composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane.
A prospective, interventional, U.S. Food and Drug Administration-cleared, phase 1/2a study assessing the safety and efficacy of CPCB-RPE1 in patients with non-neovascular age-related macular degeneration has now completed enrollment.
Copyright © 2023 Regenerative Patch Technologies, LLC - All Rights Reserved.